DiaDeep
DiaDeep is a medical technology company founded by pathologists that provides biomarker quantification and prognosis prediction solutions for early-stage melanoma using histology slides.
Classification
Profile
Funding
Funding details not yet available.
Compliance
Fundraising & market
Derives survival insights from histology in early-stage melanoma using AI, offering precise prognosis prediction to reduce diagnostic uncertainty.
Pathology laboratories and healthcare providers requiring CE-IVDR compliant biomarker quantification and prognosis tools.
RUO (Research Use Only) licensing for applied slide analysis, with potential for IVDR commercialization.
Research collaborations and direct engagement with pathology labs utilizing their 10,000+ slide application base.
Founded by 41 pathologists; open for research collaboration to validate survival insights from histology.
R&D for AI biomarker quantification, regulatory compliance (CE-IVDR), and maintaining clinical validation datasets.
Proprietary AI algorithms for biomarker quantification, 500+ patient case research evidence, and a team of 41 pathologists.
Developing CE-IVDR compliant biomarker quantification tools, validating prognosis predictions, and supporting daily lab operations.
Research-led engagement and collaboration, addressing the anxiety of waiting for precise diagnostic answers.
Competes in digital pathology AI; differentiates via founder-led pathologist expertise and specific early-stage melanoma survival insights.
Diagnostic uncertainty, anxiety of waiting for results, and the need for precise survival prognosis in early-stage melanoma.
- Expand Digital Presence & Thought Leadership - Launch a regular “AI Pathology Insights” podcast and LinkedIn series featuring case studie
- Clinical Validation at Scale - Multi-center studies published on the website demonstrate >89 % accuracy for PD-L1 scoring and robust prog
No investors recorded yet.